Merck said FDA has accepted and granted priority review for a new supplemental Biologics License Application seeking approval for Keytruda, an anti-PD-1 therapy, as a treatment for previously treated patients with advanced hepatocellular carcinoma.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
